Publications scientifiques sur le VIH

Long-term health benefit of ibalizumab in the treatment of adults with multidrug-resistant HIV-1 infection.
2018
Brogan AJ, Talbird SE, Davis AE, et al.
Oral presentation at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR); May 19-23 2018; Baltimore, Maryland, USA.
Ibalizumab for the treatment of multidrug resistant (MDR) HIV-1 Infection.
2018
Emu B.
Oral presentation at: European Meeting on HIV & Hepatitis 2018; May 30-June 1 2018; Rome, Italy.
Ibalizumab: first global approval.
2018
Drugs.
Markham A.
78(7):781-785.
Learn more
Ibalizumab in multidrug-resistant HIV - accepting uncertainty.
2018
N Engl J Med.
Sheikh V, Murray JS, Sherwat A.
379(7):605-607.
Learn more
Ibalizumab susceptibility in patient HIV isolates resistant to antiretrovirals [abstract].
2018
Top Antivir Med.
Weinheimer S, Cohen Z, Marsolais C, Lewis S.
"26(suppl 1):239s. Proceedings of the 2018 Conference on Retroviruses and Opportunistic Infections. "
Learn more